| Identification | Back Directory | [Name]
SARS-CoV-IN-6 | [CAS]
2244671-47-2 | [Synonyms]
SARS-CoV-IN-6
2,4(1H,3H)-Pyrimidinedione, 5-[[[(1R,5S)-1,3,4,5,6,8-hexahydro-8-oxo-3-(phenylmethyl)-1,5-methano-2H-pyrido[1,2-a][1,5]diazocin-9-yl]amino]methyl]-1,3-dimethyl- | [Molecular Formula]
C25H29N5O3 | [MOL File]
2244671-47-2.mol | [Molecular Weight]
447.53 |
| Hazard Information | Back Directory | [Uses]
SARS-CoV-IN-6 (Compound 17) is an inhibitor of SARS-CoV-1 and SARS-CoV-2 RdRp, with an IC50 value of 7.8 μM against SARS-CoV-2 RdRp. SARS-CoV-IN-6 reduces cytopathic effects in cells infected with SARS-CoV-1 and SARS-CoV-2 replicon-based single-round infectious particles (SRIPs), and inhibits SARS-CoV N protein expression, with EC50 values of 0.12 μM for SARS-CoV-1 replicon-based SRIPs and 1.47 μM for SARS-CoV-2 replicon-based SRIPs[1]. | [References]
[1] Chen Y, et al. Assessing the inhibitory effects of some secondary amines, thioureas and 1,3-dimethyluracil conjugates of (-)-cytisine and thermopsine on the RNA-dependent RNA polymerase of SARS-CoV-1 and SARS-CoV-2. Bioorg Med Chem Lett. 2024 Sep 7;113:129950. DOI:10.1016/j.bmcl.2024.129950 |
|
|